Director Vincent Michael Lawton of Addex Therapeutics Ltd. filed a Form 4 on November 13, 2026, disclosing the acquisition of 942,854 stock options on November 11, 2026, with an exercise price of $0.026 per share and an expiration date of October 11, 2036.
Key Highlights
- Transaction date: November 11, 2026, with 942,854 stock options (rights to buy) acquired by Director Vincent Michael Lawton.
- Exercise price: $0.026 per share, converted from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026.
- Price paid: $0 for the derivative securities at time of grant, according to the filing.
- Vesting schedule: Options vest in equal monthly installments over a 4-year period beginning at the exercisable date of November 11, 2026.
- Expiration: Options expire on October 11, 2036.
- Post-transaction holdings: Lawton beneficially owns 1,444,452 derivative securities (direct) following the reported transaction.
- Underlying security: Each option grants the right to purchase one ADXN share listed on SIX Swiss Exchange.
Addex Director Lawton Receives 942,854 Stock Options in November 2026 Grant
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 13, 2026, Vincent Michael Lawton, identified as a director of Addex Therapeutics Ltd. (NASDAQ:ADXN), acquired 942,854 stock options through a transaction coded "A" (acquired) on November 11, 2026. The filing lists Lawton's address as Chemin des Mines 9, Geneva, Switzerland, and was signed by Lenaic Nathanael Teyssedou by power of attorney.
The options carry an exercise price of $0.026, which the filing states "reflects the conversion from CHF to USD at an exchange rate of $1.1995 per CHF 1.00 as of November 11, 2026." The price of the derivative security at the time of grant was reported as $0. Each option grants the right to purchase one ADXN share listed on the SIX Swiss Exchange. The filing notes that the options "vest on equal monthly installments over a 4-year period beginning at the exercisable date," which is listed as November 11, 2026, with an expiration date of October 11, 2036.
Following the reported transaction, Lawton's total beneficial ownership of derivative securities stands at 1,444,452, held directly, according to the filing. No non-derivative securities transactions were reported in Table I of the form.
What Was Disclosed
The filing disclosed the acquisition of 942,854 stock options by Director Vincent Michael Lawton of Addex Therapeutics Ltd. on November 11, 2026, at an exercise price of $0.026 per share, bringing his total direct beneficial ownership of derivative securities to 1,444,452.




Please wait processing your request...